Fringe benefits
When we last covered psychedelic medicine in 2023, startups were racing ahead of a regulatory environment that hadn't yet caught up. Last week, that flipped. An executive order directed the FDA to fast-track psychedelics for serious mental illness, and ARPA-H—the government’s moonshot health research arm—launched a $139M behavioral health initiative, with $50M earmarked for psychedelic research. By Friday, the FDA had issued national priority vouchers to three companies studying psilocybin and methylone (an MDMA analogue) for depression and PTSD, and cleared an early-phase study of an ibogaine-based drug for alcohol use disorder. Researchers have been building an evidence base for years (as millions of Americans have been trialing microdoses)—but much of the push behind these most recent shifts seemed to come from mounting state policy efforts, the MAHA coalition, and a text from Joe Rogan.
What’s now unfolding is a real-time policy experiment—testing if regulatory acceleration can pull the science, and the market, forward. Digital health investment in psychedelics has been quiet for several quarters but these new regulatory tailwinds may reheat the category. Even still, reimbursement and infrastructure remain unsolved. Psychedelic-assisted therapy doesn't fit cleanly into how payers currently reimburse: it's not just a drug, and it's not just therapy. And at-home ketamine use, which took off with the pandemic telehealth boom, revealed a gap between access and care quality, with distribution outpacing well-delivered care. Whether digital health is ready to build (or rebuild) in this space is a different question than whether Washington is ready to let it.
Headlines
CMS, FDA Unveil Speedier Medicare Coverage Pathway For Breakthrough Devices
New fast-track model links device reimbursement to patient outcomes MedTech Dive
OpenAI’s Head Of Health Lays Out The AI Giant’s Healthcare Ambitions
From clinical workflows to consumer health, OpenAI is moving fast Endpoints News
Amazon’s One Medical Launches Comprehensive GLP-1 Program
End-to-end weight loss care is now available through Amazon Pharmacy Axios
Utah Medical Board Calls For Immediate Suspension Of AI Doctor Experiment
Alarm grows over unresolved safety risks STAT
Injectable Peptides Are The Latest TikTok Wellness Fad. Doctors Are Worried
Social media is outpacing the science, and regulators, behind injectable peptides The Wall Street Journal
Recent Funding
- AcuityMD inks $80M for its commercial intelligence platform for MedTech companies
- Cala Health nabs $50M to scale its FDA-cleared wearable neuromodulation therapy for tremors
- Courier Health scores $50M for its biopharma patient journey platform
- Tava Health, a mental health platform for providers, employers, and plans, raises $40M
- Amperos Health grabs $16M for its denial management and revenue recovery platform
- Zócalo Health snags $15M for its community-based primary care model
- Coral raises $12.5M for its administrative workflow platform for specialty providers
- Clinical decision support platform, Almanac Health secures $10M
- Gravity Rail launches with $2.75M to help healthcare teams build and deploy AI workflows